Search results for: Pricing and Reimbursement
Filter search results
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…will affect productivity; how collaboration and competition stimulate learning and commercialisation; and the changing roles of large and small biopharmaceutical companies, academia, governments, and payers. The conference will consider specific…
Spotlight on OHE: Development and Use of Measures of Health Worldwide
16 July 2012
…Netherlands, and the United States – and plans for EQ-5D-5L Value Sets studies in 2012 and beyond. At ISPOR, Nancy also presented two poster sessions that examined the EQ-5D’s use…
OHE Conference on Drug Development in 2022: Update
18 July 2012
…conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development. OHE has added important panelists and…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
…using diagnostic and therapeutic tests in tandem with treatment—“co-dependent technologies”—potentially can maximise both treatment effectiveness and economic efficiency. Advances in science and technology are producing more and better means for…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…Adrian Towse from Office of Health Economics Related OHE publications and materials include the following. Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should…
Social Preferences and Burden of Illness in Value-based Assessments
11 February 2014
…improvement and end of life for value based pricing, which she co-authored with colleagues in the Department of Health Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU)…
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. A…
Spotlight on OHE: NICE, Biosimilars, HTA
17 June 2014
…that are part of the value based assessment consultation. She illustrated how two suggested decision-making factors, burden of illness and wider societal impact, might be measured and calculated for specific…
OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value
22 October 2014
…publicly available sources and an online survey. The countries included are Australia, Canada, Denmark, France, Italy, Korea, The Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia-Herzegovina, Ecuador, Egypt and Ghana. (PHP86,…